Effective Date: October 1, 2021
INTRODUCTION
This website (the “Site”) is owned and operated by Tryp Therapeutics Inc. (“Tryp,” “us,” “our,” or “we”). These Terms of Use (“Terms of Use “) set forth the terms and conditions under which you are authorized to use our our website at www.tryptherapeutics.com (the “Site”).
ADDITIONAL POLICIES AND AGREEMENTS
Our Privacy Policy describes the information we collect when you use our Site or interact with us, as well as how we use the information, and some of the steps we take to protect your privacy. Our Privacy Policy is part of these Terms of Use. By agreeing to these Terms of Use, you are also consenting to our use of your personal information in accordance with our Privacy Policy. To the extent additional rules or guidelines affect your use of the Site or your online transactions with us, those rules are hereby incorporated by reference into these Terms of Use. By using our Site, you agree to these Terms of Use. If you do not agree to these Terms of Use, you should immediately stop using our Site.
DESCRIPTION OF SERVICE
Our Site provides information about Tryp and allows users to request further information, indicate interest in clinical trials, and more (collectively the “Services”). To the extent new offerings, content or features are added to our Site in the future, your use thereof is subject to these Terms of Use.
YOUR OBLIGATIONS
If you enter into a transaction on our Site or otherwise contact us through the Site, you agree to provide accurate information about yourself. We reserve the right to suspend or terminate your use of our Site and to revoke permission for you to use our Services if we discover, or if we have a reasonable basis to believe, that any of the data you have provided is inaccurate, incomplete or untrue, or if you violate these Terms of Use.
MODIFICATIONS AND INTERRUPTION TO THE SITE
We reserve the right to modify or discontinue all or any portion of our Site with or without notice to you. We will not be liable if we choose to exercise this right. You acknowledge and accept that we do not guarantee continuous, uninterrupted or secure access to our Site, or that operation of our Site will be uninterrupted or error free. You understand that usage of our Site may be interfered with or adversely affected by numerous factors or circumstances outside of our control.
THIRD-PARTY SITES, CONTENT AND SERVICES
Certain areas of the Site may include content or services provided by third parties, or links to other sites that are owned and operated by third parties. We are not responsible for the availability of, or any content located on or through, any third-party site, or any services provided by third parties. You acknowledge that any reliance on representations and warranties provided by any party other than Tryp will be at your own risk. You expressly agree to hold us harmless for any claims of damage arising from any content, product or service provided by any third party. Your use of those third-party sites and services is subject to the terms of use and privacy policies posted on each site or service, and we encourage you to review those terms of use and privacy policies.
YOUR REPRESENTATIONS
As a condition of your right to use the Site, you represent that you are of legal age to enter into a binding contract and that you are not a person barred from visiting the Site and accessing the Services under the laws of the United States or other country.
DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY
TO THE FULLEST EXTENT PERMITTED BY LAW, THE TRYP, ITS RELATED ENTITIES, ITS SERVICE PROVIDERS, ITS LICENSORS, AND ITS OR THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES OR AGENTS (COLLECTIVELY THE “TRYP PARTIES”) EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT, RELATED TO OUR SITE. YOU UNDERSTAND AND AGREE THAT YOUR USE OF OUR SITE IS AT YOUR SOLE RISK. OUR SITE AND ALL CONTENT, PRODUCTS AND SERVICES OFFERED THROUGH THE SITE ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. THE TRYP PARTIES ARE NOT RESPONSIBLE FOR THE TIMELINESS OF DELIVERY OF CONTENT, ANY FAILURES OF DELIVERY, ERRONEOUS DELETION OR FAILURE TO STORE ANY OF YOUR PERSONAL SETTINGS OR COMMUNICATIONS, OR ANY LOSS OR DAMAGE OF ANY KIND YOU CLAIM WAS INCURRED AS A RESULT OF THE USE OF OUR SITE. UNDER NO CIRCUMSTANCES, WILL ANY OF THE TRYP PARTIES BE LIABLE TO YOU OR TO ANY PERSON OR ENTITY CLAIMING THROUGH YOU FOR ANY LOSS, INJURY, LIABILITY OR DAMAGES ARISING OUT OF OR IN CONNECTION WITH YOUR ACCESS TO, USE OF, INABILITY TO USE, OR RELIANCE ON OUR SITE OR ANY CONTENT, PRODUCT OR SERVICE PROVIDED TO YOU THROUGH OR IN CONNECTION WITH OUR SITE. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL LOSSES AND DAMAGES OF ANY KIND WHATSOEVER, WHETHER DIRECT OR INDIRECT, GENERAL, SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR OTHERWISE, INCLUDING WITHOUT LIMITATION, LOSS OF DATA, GOODWILL, REVENUE OR PROFITS. THIS LIMITATION OF LIABILITY APPLIES WHETHER THE ALLEGED LIABILITY IS BASED ON CONTRACT, NEGLIGENCE, TORT, STRICT LIABILITY OR ANY OTHER BASIS; EVEN IF ANY TRYP PARTY HAS BEEN ADVISED OF OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES; AND WITHOUT REGARD TO THE SUCCESS OR EFFECTIVENESS OF OTHER REMEDIES. IF ANY PART OF THIS LIMITATION OF LIABILITY IS FOUND TO BE INVALID, ILLEGAL OR UNENFORCEABLE FOR ANY REASON, THEN THE AGGREGATE LIABILITY OF THE TRYP PARTIES UNDER SUCH CIRCUMSTANCES TO YOU OR ANY PERSON OR ENTITY CLAIMING THROUGH YOU FOR LIABILITIES THAT OTHERWISE WOULD HAVE BEEN LIMITED WILL NOT EXCEED ONE HUNDRED U.S. DOLLARS. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF CERTAIN WARRANTIES OR THE LIMITATION OR EXCLUSION OF LIABILITY FOR CERTAIN TYPES OF DAMAGES. ACCORDINGLY, SOME OF THE ABOVE DISCLAIMERS OF WARRANTIES AND LIMITATIONS OF LIABILITY MAY NOT APPLY TO YOU.
INDEMNIFICATION
You agree to indemnify and hold the Tryp Parties harmless from any claim or demand, including reasonable attorney’s fees and costs, made by any third party due to or arising out of your posting of any content on our Site in a manner not permitted by these Terms of Use, including without limitation your actual or alleged violation of these Terms of Use, or infringement of a third party’s intellectual property or other rights by you or another user of our Site using your computer, mobile device or account.
FORWARD LOOKING INFORMATION
Our Website contains forward looking statements with respect to Tryp. By their nature, forward looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward looking statements. In addition, the forward looking statements require Tryp to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward looking statements will not prove to be accurate, that Tryp’s assumptions may not be correct and that actual results may differ materially from such forward looking statements. Accordingly, readers should not place undue reliance on the forward looking statements. Generally, forward looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “potential” and similar expressions. Forward looking statements contained in this Website may include, but are not limited to statements with respect the outlook for the psilocybin industry and related industries; challenges and opportunities related to the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Tryp’s patent applications to protect the commercial prospects of its assets; the achievement, and the timing of, certain development milestones and the successful execution of Tryp’s business strategy (including its business model and mission); the use and benefits of Tryp’s products and services; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Tryp’s ability to obtain marketing exclusivity for any of its approved drug products; anticipated capitalization, projected milestones and the go-forward management of Tryp; the potential impact of the COVID-19 pandemic on Tryp’s business or operations; and other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance, expected regulatory filings, review and approval dates, and start-up timelines and schedules, and statements related to the continued overall advancement of Tryp’s business. These forward looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to: general economic, market and business conditions, the outcome of research studies, the ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. All forward looking statements contained in this Website are expressly qualified by this cautionary statement.
THIRD-PARTY INFORMATION
This Website includes market and industry data obtained from various publicly available sources and other sources believed by Tryp to be true. Although Tryp believes it to be reliable, Tryp has not independently verified any of the data from third-party sources referred to in this Website or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. Tryp does not make any representation as to the accuracy of such information.
PSILOCYBIN
Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the “CDSA”) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While Tryp is focused on developing products using psilocybin, it does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. Tryp does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. Tryp’s products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.
USER FEEDBACK
All communications, feedback, questions, comments, suggestions, proposed features, and the like (collectively “Feedback”) will be considered non-confidential and non-proprietary with regard to you, but we reserve the right to treat any such Feedback as the confidential information of Tryp. By submitting Feedback to us, you assign to us, free of charge, a perpetual, irrevocable, worldwide license to create derivative works, distribute, reproduce, perform, display, and otherwise use, any intellectual property rights or proprietary information and ideas contained within any such Feedback, including without limitation the right to sublicense or assign any of the foregoing. We will be entitled to use any Feedback you submit to us, and any ideas, concepts, know-how or techniques contained in any such Feedback, for any purpose whatsoever, including but not limited to developing and marketing products and services using such Feedback without restriction and without notifying or compensating you in any way. Please do not send us any information or materials for which you do not wish to grant us such rights, including, without limitation, any confidential information or any original creative materials such as product ideas, written materials, photographs, original artwork, or computer code. You are responsible for the information and other content contained in any Feedback you submit to us, including, without limitation, their truthfulness and accuracy.
USER-SUBMITTED CONTENT AND USER CONDUCT
Any content, whether uploaded, posted, submitted, or otherwise made available to us or on our Site, including without limitation comments to blog posts, user content from social media, or any other content which does not originate with a Tryp Party (“User Content”), is the sole responsibility of the person who made such User Content available. Under no circumstances will any Tryp Party be liable in any way for any User Content made available through our Site. You agree that you will not use our Site to transmit or make available any content that:
You further agree not to use our Site to:
In addition, you are prohibited from interfering with, creating an excessive burden on, or otherwise disrupting our Site, servers or networks connected thereto. We reserve the right (but have no obligation) in our sole discretion to pre-screen, edit, refuse, move or remove any User Content that is posted on our Site or prohibit your access to our Site in the event of a violation of these Terms of Use.
COPYRIGHT AND TRADEMARK INFORMATION
All content, copyrights and other intellectual property rights in the content available on our Site, including without limitation the Site’s design, text, graphics, interfaces, and the selection and arrangements thereof, are owned by Tryp, with all rights reserved, or in some cases may be licensed to Tryp by third parties. This content is protected by the intellectual property rights of Tryp or those owners. All content which qualifies for protection under Federal Copyright Law under the laws of the United States is subject to the exclusive jurisdiction of the Federal Court System, whether registered or unregistered. All trademarks displayed on the Sites are the trademarks of their respective owners, and constitute neither an endorsement nor a recommendation of such parties. In addition, such use of trademarks or links to the web sites of third parties is not intended to imply, directly or indirectly, that those third parties endorse or have any affiliation with Tryp. If you believe that any content on our Site violates these Terms of Use or is otherwise inappropriate, please report the content by completing the Contact Us form on our Site, or send an email to legal@cograilway.com.
ARBITRATION
Any dispute arising out of or relating in any way to your use of our Site or any products, services, or information you receive through our Site, shall be submitted to confidential, binding arbitration in Colorado Springs, Colorado, USA, pursuant to the American Arbitration Association’s Commercial Arbitration Rules. The arbitrator’s award shall be final and binding and may be entered as a judgment in any court of competent jurisdiction. No arbitration under these Terms of Use may be joined with another arbitration related to the subject matter hereof. Notwithstanding the foregoing arbitration requirement, with regard to any actual or potential violation of our intellectual property rights, we may seek injunctive or other appropriate relief in the courts of Colorado Springs, Colorado, USA, and you hereby consent to the exclusive jurisdiction of such courts and waive all objections thereto.
GOVERNING LAWS
The laws of the province of British Columbia and Canada govern these Terms of Use and any claims arising out of or relating to use of the Site and our Services, without giving effect to any choice of law rules. We make no representation that our Site is appropriate, legal or available for use outside of the United States. With the exception of any matters subject to arbitration as described above, the provincial and federal courts located in British Columbia will serve as the venue for any actions brought, or claims made, arising out of your use of our Site or Services.
COMPLIANCE WITH LAWS
You assume all knowledge of applicable law and you are responsible for compliance with any such laws. You may not use the Site in any way that violates applicable state, federal, or international laws, regulations or other government requirements.
CHANGES TO THESE TERMS
We reserve the right, at any time, to modify, alter, or update these Terms of Use without prior notice. You are encouraged to check this page regularly for changes to the Terms of Use. Modifications will become effective immediately upon being posted to our Site, without further notice to you. Your continued use of any of our Sites after such modifications are posted constitutes an acknowledgement and acceptance of such modifications, and you may not amend these Terms of Use.
MISCELLANEOUS
If any provision of these Terms of Use is determined by a court of law to be unlawful, void or unenforceable for any reason, the other provisions (and any partially-enforceable provision) shall not be affected thereby and shall remain valid and enforceable to the maximum possible extent, and the invalid provision will be modified as necessary to make it valid and enforceable while as closely as possible reflecting the original intentions of Tryp. You agree that these Terms of Use and any other agreements referenced herein may be assigned by us, in our sole discretion, to a third party in the event of a merger or acquisition or otherwise. These Terms of Use shall apply in addition to, and shall not be superseded by, any other written agreement between us in relation to your participation as a contributor to or user of our Site. You agree and understand that these Terms of Use together with any other applicable click-through agreements you may have entered into regarding posting User Content to our Site, and any additional terms incorporated herein, constitute the entire agreement between you and Tryp regarding your use of the Site, and that any other prior agreements between you and Tryp are superseded by these Terms of Use. Any failure by Tryp to exercise its rights under these Terms of Use or to enforce the terms hereof, will not constitute a waiver of those rights. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to use of our Site or relating to these Terms of Use must be filed within one (1) year after such claim or cause of action arose or be forever barred.
CONTACT US
If you have any questions about these Terms of Use, please emails us at privacy@tryptherapeutics.com.
Chief Financial Officer
Mr George is a Director at Bio101 Financial Advisory (‘Bio101’), a financial services firm providing outsourced CFO, taxation and company secretarial solutions to the biotechnology and healthcare sector. He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits.
He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant.
Scientific Advisor
Professor Philippa Hay is a renowned academic psychiatrist with international recognition for her research on eating disorders and obesity. With over 500 scientific papers and significant contributions to clinical practice and treatment guidelines, she has influenced national and international standards.
Notably, she led the development of the Royal Australian and New Zealand College of Psychiatrists’ national guidelines and the EDP framework for Medicare-supported recovery in Australia. Awarded the ANZ Academy for Eating Disorders Lifetime Leadership Award and the RANZCP Senior Research Award, she is also the founding Editor-in-Chief of the Journal of Eating Disorders and a past-President of the Australian Academy for Eating Disorders.
Her current research includes clinical trials for anorexia nervosa, public health interventions, and the exploration of psychedelics in treatment. She serves as a principal reviewer for the Cochrane Library and frequently contributes to leading journals and publications.
Scientific Advisor
Professor David Castle is a distinguished psychiatric scholar, who most recently was appointed by the Tasmanian Government as Professor of Psychiatry at the University of Tasmania’s Centre for Mental Health Service Innovation, launched in partnership with the Tasmanian Department of Health.
Previously, he served as the Inaugural Scientific Director at the Centre for Complex Interventions and the Centre for Addictions and Mental Health at the University of Toronto, and as Professor of Psychiatry at the University of Melbourne. With a focus on mental health conditions such as schizophrenia, bipolar disorder, and OCD, he is known for his research on psychedelic treatments and body dysmorphic disorder.
Professor Castle has published over 900 works, reviews for numerous scientific journals, and has a strong track record in securing significant research funding.
Scientific Advisor
William Schmidt, PhD is a Scientific Advisor to Tryp Therapeutics.
Dr. Schmidt serves as an expert on pain medicine pharmaceutical development with pharmaceutical and biotech companies throughout North America, Europe, Asia, Latin America and Australia. He currently sits on the Scientific or Medical Advisory Boards of five biotech companies. Dr. Schmidt has received many awards throughout his career including the John J. Bonica award for the development of new analgesics and for his sustained contributions to the educational efforts of the Eastern Pain Association in 2014. He joined DuPont Pharmaceuticals where he helped to develop nalbuphine (Nubain®), naltrexone (Trexan®, ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. He also led the clinical teams in the development of alvimopan (Entereg®) and polmacoxib (Acelex®).
Dr. Schmidt earned a BA from the University of California, Berkeley and a PhD from University of California, San Francisco.
Scientific Advisor
Derek Ott, MD is a Scientific Advisor to Tryp Therapeutics.
Dr. Ott is an Associate Clinical Professor of psychiatry at the UCLA School of Medicine, Director of the UCLA Pediatric Neuropsychiatry Clinic and a psychiatric consultant for Westside and Frank D. Lanterman Regional Centers in Los Angeles. He is a board-certified physician in child, adolescent and adult psychiatry. Dr. Ott has particular expertise in the areas of neuropsychiatry, developmental disabilities, attention-deficit hyperactivity disorder and childhood psychosis. His private practice focuses on psychopharmacology in children, adolescents and adults.
Dr. Ott earned a BS in human biology from Stanford University. He then attended the University of Illinois Urbana-Champaign, where he earned an MS in neuroscience and an MD.
Scientific Advisor
Rachel Wevrick, PhD is a Scientific Advisor to Tryp Therapeutics.
Dr. Wevrick is a Professor in the Department of Medical Genetics at the University of Alberta. Her research is focused on the genetic, molecular and physiological basis of abnormal neurodevelopment, growth and metabolism in developmental disorders affecting children. Her specific areas of interest include Prader-Willi syndrome, Schaaf-Yang syndrome and other neurodevelopmental disabilities that are caused by genetic mutations.
Dr. Wevrick earned a PhD from the Department of Molecular and Medical Genetics, University of Toronto and completed post-doctoral fellowships in the Department of Genetics at the Hospital for Sick Children Research Institute and at the Howard Hughes Medical Institute, Stanford University School of Medicine.
Scientific Advisor
Joel Castellanos, MD is a Scientific Advisor to Tryp Therapeutics.
Dr. Castellanos is an Associate Professor in the Department of Anesthesiology at the UC San Diego School of Medicine. He also serves as Medical Director of Inpatient Rehabilitation. Dr. Castellanos has specific clinical interests in pelvic pain, complex regional pain syndrome, phantom limb pain and post-spinal cord injury pain syndromes. His research interests include altering nutrition as a means of treating chronic pain, neuromodulation for chronic painful conditions and the potential use of psychedelics for these conditions.
Dr. Castellanos completed residency training in physical medicine and rehabilitation at University of Michigan Medical School, where he also completed a two-year program in healthcare administration. Dr. Castellanos earned his medical degree from University of Toledo College of Medicine in Ohio. He is board-certified in physical medicine and rehabilitation and pain medicine.
Scientific Advisor
Daniel Clauw, MD, is a Scientific Advisor to Tryp Therapeutics.
Dr. Clauw is a Professor of anesthesiology, medicine (Rheumatology) and psychiatry at the University of Michigan. He serves as Director of the Chronic Pain and Fatigue Research Center. He joined the faculty at Georgetown University in 1990, and while there, founded the Georgetown Chronic Pain and Fatigue Research Center, and served as the Division Chief of Rheumatology, Immunology and Allergy, and Vice Chair of the Department of Medicine. Since moving to UM in 2001, Dr. Clauw has continued his commitment to the clinical care and research into overlapping conditions such as Fibromyalgia, Gulf War Illnesses, and Interstitial Cystitis, just to name a few. Dr. Clauw has become an internationally known expert in chronic pain, and especially the central nervous system contributions to chronic pain states, performing past or ongoing work in conditions such as low back pain, osteoarthritis, vulvodynia, endometriosis, irritable bowel syndrome and temporomandibular joint disorder.
Dr. Clauw attended the University of Michigan for both undergraduate and medical school studies and then completed his Internal Medicine residency and Rheumatology Fellowship at Georgetown University.
Chairman, Scientific Advisory Board
Robin Carhart-Harris serves as Chairman of the Scientific Advisory Board for Tryp Therapeutics.
Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. He is also the Director of the Psychedelics Division within the translational neuroscience center, Neuroscape, at UCSF. Dr. Carhart-Harris founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind. He has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT; a clinical trial of psilocybin for treatment-resistant depression; a double-blind randomized controlled trial comparing the effects of psilocybin and the SSRI escitalopram on depression that was published in the New England Journal of Medicine; and a multimodal imaging study in first-time users of psilocybin.
Dr. Carhart-Harris earned a BSc in applied psychology and computing from Bournemouth University, an MA in psychoanalysis and contemporary science from Brunel University, and a PhD in psychopharmacology from the University of Bristol. He has published over 100 scientific papers and in 2021 was listed in Time Magazine’s “100 Next,” a list of 100 rising stars shaping the future.
Non-Executive Director – B.Comm, MAICD
Clarke is a Financial Adviser and Capital Markets Specialist with over 20 years’ experience in the Financial Services Industry in Australia and the United Kingdom.
Clarke has experience in structuring, operations and risk management of institutional exotic derivatives in the United Kingdom with Morgan Stanley International Limited and has been a Derivatives Manager, responsible for establishing and managing derivatives trading desks for several Australian based stockbroking firms.
Clarke brings to Exopharm his extensive experience providing corporate advisory services for companies listed on the Australian Securities Exchange (ASX) across a variety of industries, with a particular focus on growth opportunities in the Biotechnology, Technology, Industrial and Resource industries, providing them with advice on business models & strategy, structuring of pre-IPO and IPO fund raisings, reverse takeovers, capital raisings, mergers and acquisitions, investor relations and capital markets advice.
Clarke also services institutional, wholesale and retail clients, advising on ASX investments, share portfolios, derivatives, and identification of early-stage opportunities across a variety of industries and sectors.
Clarke is a Founding Director of AMG Acquisition Corp, a publicly listed company on the Toronto Venture Exchange.
Clarke holds a Bachelor of Commerce degree from the University of Western Australia and is a Member of the Australian Institute of Company Directors (AICD).
Chairman
Mark is Founder and Managing Director at 1861 Capital and has been an investor in Exopharm since the IPO in 2018. Mark has a Bachelor of Commerce from the University of Western Australia and is Non-Executive Chairman of Neurotech International (ASX: NTI), a drug development company focused on utilising NTI164 in the treatment for paediatric neurological disorders including Autism Spectrum Disorder (ASD).
Non Executive Director – B.Comm
Mr Ntoumenopoulos is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm.
He has extensive experience in financial markets, with over 20 years of raising capital and providing corporate advisory services. Additionally, he has served as a director of ASX listed companies for more than 7 years.
Mr Ntoumenopoulos was a founding director of both ResApp Health Ltd (ASX:RAP), which was acquired by Pfizer, and Race Oncology (ASX:RAC). Currently, he serves as a non-executive director at TrivarX Limited (ASX:TRI).
If elected, Mr Ntoumenopoulos will be considered by the Board (including the incoming Directors with Mr Ntoumenopolous abstaining) to be an independent Director. Mr Ntoumenopoulos is not considered by the Board to hold any interest, position or relationship that might influence, or reasonably be perceived to influence, in a material respect his capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the entity as a whole rather than in the interests of an individual security holder or other party. Mr Ntoumenopoulos does not currently hold any other material directorships, other than as disclosed in this Prospectus.
Non Executive Director
Gage Jull serves as a Chairman of Tryp Therapeutics.
Gage is Executive Chairman of Arrow Exploration, a TSX-V and London AIM listed oil and gas exploration and production Company (TSX-V; AIM: AXL). Arrow has grown production, cleaned up its balance sheet and is growing its cashflow. Prior to Arrow, Gage was a Co-Founder and Chairman of Bordeaux Capital Inc., a Toronto-based mergers & acquisitions advisory firm focused on emerging companies in the natural resources and other sectors. Before Bordeaux Capital, Mr. Jull was a Managing Director, Corporate Finance at Mackie Research Capital Corp., an investment banking and securities brokerage firm. Mr. Jull has acted as lead underwriter on numerous cross border equity and debt offerings involving energy assets around the world, with capital sourced in Canada, the U.S. and the U.K. At Prudential Bache, Mr. Jull was the lead banker on the $40 million cross border IPO of Quadra Logic Technologies, a Vancouver based pharmaceutical company. He has completed over 200 financings and M&A transactions in the course of his career.
Mr. Jull holds a BSc degree from the University of Toronto, an MBA from the University of Western Ontario, and holds both PEng and CFA designations.
Company Secretary
David is a Director and Principal of the Automic Group. As a Senior Executive, Company Secretary and Director of ASX Listed Entities and Professional Services organisations, David has over 25 years of experience within this field, in a diverse range of industries.
David is a Chartered Accountant, Fellow of the Financial Services Institute of Australasia, Fellow of the Governance Institute of Australia, Justice of the Peace, Registered Tax Agent and holds a Bachelor of Economics (Finance and Accounting) from Macquarie University.
With over 25 years in finance and accounting, initially qualifying with Price Waterhouse in their Business Services and Corporate Finance Divisions, David has been CFO, Company Secretary and/or Director for numerous ASX listed and unlisted public and private companies, in a range of industries including energy retailing, software as a service, transport, financial services, mineral exploration, technology, automotive, software development wholesale distributions, retail, biotechnology and healthcare.
VP, Drug Development
Peter Guzzo, PhD serves as Vice President of Drug Development at Tryp Therapeutics.
Pete served as Director of Drug Discovery at Curia (formerly AMRI) for nearly 20 years where he led drug discovery teams from project conception through clinical trials. While at Curia, Pete developed products and intellectual property in the areas of CNS, oncology and gastrointestinal diseases. Pete co-founded and served as CEO at ConSynance Therapeutics, a clinical-stage drug development company pursuing treatments for rare diseases.
Pete earned a BS in chemistry from Assumption College and a PhD in organic chemistry from the University of Notre Dame. He is an inventor on 43 patents, has co-authored 47 scientific publications, and has presented nearly 30 invited lectures.
President & Chief Scientific Officer – Ph.D., MSIB.
Jim Gilligan currently serves as Chief Executive Officer, President and Chief Scientific Officer of Tryp.
Jim received his Ph.D in pharmacology and Toxicology from the University of Connecticut. He pursued his post-doctoral fellowship at the Roche Institute of Molecular Biology. Later in his career he returned to Seton Hall University where he earned an MBA in International Business.
Jim is a scientist, entrepreneur, executive, and business development specialist who has over 35 years in the pharmaceutical industry and co-founded and helped lead multiple bio-pharma and bio-tech companies, including Tryp, Tarsa Therapeutics, Herborium Inc., and Unigene Labs, where he oversaw the entire spectrum of drug development activities, including pharmacology and preclinical activities, CMC, clinical Phase I-III, as well as US and international regulatory strategies. Jim is a co-author on several manufacturing and formulation patents and has been featured in journal articles on novel therapeutic peptides and their clinical utility. He has executed numerous feasibility and licensing deals within the pharmaceutical industry, working frequently with investment bankers, venture capitalists, and brokers.
Chief Medical Officer
Michael Silverman, MD serves as the Chief Medical Officer of Tryp.
Michael has over 30 years of experience in clinical development in biotech including product development strategy, clinical/regulatory planning and operations, business strategic analysis and planning, and technical assessment and recommendations. Additionally, Michael has served as President of BioStrategics Consulting Ltd. since 1999.
Michael received his BS from the University of Illinois and his MD from the University of Chicago Pritzker School of Medicine.
Chief Business Officer
BA (Hons), CFA (UK)
Mr Molloy has 25 years of experience creating, advising and investing in private and public companies, with a particular focus on the healthcare sector. He was previously the founder and CEO of Edison Group where he spent 15 years building the company into an international brand with a global team in excess of 100 people, recognized for its world class equity research platform, advisory services, and deep sector expertise. He remains a Director and principle shareholder of Edison.
Mr Molloy is also the co-founder of various other companies including, most recently, Tarus Therapeutics, an immune-oncology company which was acquired by a NASDAQ listed biotech in July 2022. Mr Molloy’s earlier career includes a successful period as an institutional investor, most notably at Hermes Investment Management in London, managing a healthcare and technology focused small/mid-cap portfolio, and with a close involvement in Hermes’ shareholder activism initiatives.
Mr Molloy graduated from Exeter University (UK) with a degree in Economics and is an alumni of London Business School. He holds the CFA (UK) and FINRA Series 7.
Chief Executive Officer
Jason Caroll currently serves as Chief Executive Officer of Tryp.
Jason brings a wealth of experience as a highly regarded life sciences executive, with an impressive 32-year career in the industry. In addition to his most recent role as Managing Director of iNova Pharmaceuticals Philippines, his extensive background includes leadership roles at industry giants Johnson & Johnson, Janssen Pharmaceutica, and Bristol-Myers Squibb.
Jason received his B.Sc. in Organic Chemistry from Flinders University of South Australia and completed his Master of Business Administration in Technology Management from Deakin University.
Jason has managed roles of increasing responsibility in operations (Pharmaceutical Production Management), sales & marketing (Specialist Medical Representative, Product Management, Sales & Marketing Management & Business Unit Director) and business development (Early Product Development Lead, Associate Director of Market Access, Associate Director of Asia Regional Business Development and Business Licensing & Acquisition). His first country leadership role was as General Manager of Janssen Pharmaceutica Philippines, followed by Managing Director of One J&J Vietnam (including additional responsibilities as SEA Board representative of Janssen Pharmaceuticals Asia-Pacific and SEA Marketing Director of Immunology & Oncology and Global Board membership of the J&J Sustainability Council).
He has expertise across pharmaceuticals, biologics, medical devices, OTC & consumer medicines and is considered to be a turnaround specialist and outstanding people leader. Within his most recent role, Jason built a strong leadership team that increased iNova Pharmaceuticals Philippines sales 3 fold during his 5 year tenure.
Chief Financial Officer
Jim O’Neill – BBA, CPA and CA
Jim O’Neill currently serves as Chief Financial Officer of Tryp.
Jim has over 30 years of experience as a finance executive with publicly listed and private multi-national businesses. Most recently, he founded and serves as president of O’Neill & O’Neill Services Corp. providing financial consulting services including CFO and corporate secretarial services to TSXV and CSE listed companies.
Jim received his bachelor’s in business administration from Wilfrid Laurier University and holds a CPA and CA from the Chartered Professional Accountants of Ontario.